142 related articles for article (PubMed ID: 21103255)
1. Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C.
Martins EV; Gaburri AK; Gaburri D; Sementilli A
Case Rep Gastroenterol; 2009 Nov; 3(3):366-371. PubMed ID: 21103255
[TBL] [Abstract][Full Text] [Related]
2. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature.
Hurst EA; Mauro T
Arch Dermatol; 2005 Jul; 141(7):865-8. PubMed ID: 16027302
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
4. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
Akhan SC; Gurel E; Sayan M
Indian J Pathol Microbiol; 2011; 54(1):81-4. PubMed ID: 21393883
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
Foster GR
Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
[TBL] [Abstract][Full Text] [Related]
6. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
Kapol N; Lochid-Amnuay S; Teerawattananon Y
BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
[TBL] [Abstract][Full Text] [Related]
8. Development of sarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature.
Bolukbas C; Bolukbas FF; Kebdir T; Canayaz L; Dalay AR; Kilic G; Ovunc O
Acta Gastroenterol Belg; 2005; 68(4):432-4. PubMed ID: 16432996
[TBL] [Abstract][Full Text] [Related]
9. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
11. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Chen YC; Lu SN; Lin MC
Chang Gung Med J; 2007; 30(1):92-7. PubMed ID: 17477035
[TBL] [Abstract][Full Text] [Related]
12. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
Hashimoto Y; Kanto H; Itoh M
J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
Yenice N; Mehtap O; Gümrah M; Arican N
Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
[TBL] [Abstract][Full Text] [Related]
15. Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha-2b in chronic hepatitis C patients.
Ali S; Nazir G; Khan SA; Iram S; Fatima F
J Ayub Med Coll Abbottabad; 2010; 22(4):127-30. PubMed ID: 22455279
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
Baker DE
Rev Gastroenterol Disord; 2003; 3(2):93-109. PubMed ID: 12776006
[TBL] [Abstract][Full Text] [Related]
17. Erythema annulare centrifugum due to pegylated interferon-α-2a plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
Gönül M; Külcü Çakmak S; Ozcan N; Deniz Oǧuz I; Ozhamam E
J Cutan Med Surg; 2014; 18(1):65-8. PubMed ID: 24377478
[TBL] [Abstract][Full Text] [Related]
18. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
19. [Cutaneous sarcoidosis during pegylated interferon alpha and ribavirin treatment of chronic hepatitis C--a case report].
Honsová E; Sticová E; Sperl J
Cesk Patol; 2007 Jan; 43(1):27-30. PubMed ID: 17370474
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
